Intra Cellular Therapies (ITCI) Share Price Declined While Clough Capital Partners LP Upped Its Holding; Amalgamated Bank Has Trimmed Its Cit Group (CIT) Position by $310,905; Stock Rose

February 20, 2018 - By Adrian Erickson

Charles Clough increased its stake in Intra Cellular Therapies Inc (ITCI) by 74.8% based on its latest 2017Q3 regulatory filing with the SEC. Clough Capital Partners LP bought 281,900 shares as the company’s stock declined 19.44% while stock markets rallied. The hedge fund run by Charles Clough held 658,750 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $10.40M, up from 376,850 at the end of the previous reported quarter. Clough Capital Partners LP who had been investing in Intra Cellular Therapies Inc for a number of months, seems to be bullish on the $1.08 billion market cap company. The stock decreased 1.10% or $0.22 during the last trading session, reaching $19.75. About 187,633 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since February 20, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Amalgamated Bank decreased its stake in Cit Group Inc (CIT) by 32.19% based on its latest 2017Q3 regulatory filing with the SEC. Amalgamated Bank sold 6,345 shares as the company’s stock rose 7.62% with the market. The institutional investor held 13,366 shares of the consumer services company at the end of 2017Q3, valued at $656,000, down from 19,711 at the end of the previous reported quarter. Amalgamated Bank who had been investing in Cit Group Inc for a number of months, seems to be less bullish one the $7.05 billion market cap company. The stock decreased 0.67% or $0.36 during the last trading session, reaching $53.69. About 94,434 shares traded. CIT Group Inc. (NYSE:CIT) has risen 46.21% since February 20, 2017 and is uptrending. It has outperformed by 29.51% the S&P500.

Among 11 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Intra-Cellular Therapies had 36 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) earned “Outperform” rating by RBC Capital Markets on Friday, November 6. As per Thursday, September 7, the company rating was maintained by Cantor Fitzgerald. The company was maintained on Wednesday, August 23 by Cantor Fitzgerald. The company was maintained on Wednesday, August 9 by Piper Jaffray. Piper Jaffray maintained it with “Hold” rating and $14.0 target in Wednesday, August 23 report. SunTrust upgraded the shares of ITCI in report on Wednesday, November 8 to “Buy” rating. On Thursday, August 24 the stock rating was upgraded by JMP Securities to “Market Outperform”. The company was maintained on Wednesday, August 9 by Cantor Fitzgerald. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) earned “Overweight” rating by Piper Jaffray on Thursday, June 2. As per Wednesday, August 23, the company rating was maintained by Cowen & Co.

Investors sentiment increased to 2.77 in Q3 2017. Its up 1.91, from 0.86 in 2017Q2. It is positive, as 9 investors sold ITCI shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported. Stifel Corp reported 14,850 shares. Swiss Savings Bank reported 69,800 shares. Dekabank Deutsche Girozentrale accumulated 0.03% or 289,200 shares. Ameritas Investment Prtn reported 0% stake. Wasatch Advsr Inc invested in 1.97M shares or 0.42% of the stock. Jpmorgan Chase And, a New York-based fund reported 408,425 shares. Moreover, Omers Administration has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Millennium Mngmt Ltd Liability Corporation invested in 0.03% or 1.38M shares. 99,024 were reported by Panagora Asset Management Inc. Thrivent Fin For Lutherans accumulated 0% or 49,350 shares. Metropolitan Life Insurance Communication invested in 0% or 25,164 shares. Us Bancorporation De holds 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 1,944 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Moreover, Parallax Volatility Advisers LP has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 98,088 shares. Numeric reported 0.01% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI).

Since September 29, 2017, it had 3 insider purchases, and 9 sales for $10.92 million activity. Hineline Lawrence J. also sold $82,725 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares. ALAFI CAPITAL CO LLC had bought 258,065 shares worth $4.00 million on Monday, October 2. Halstead Michael sold $69,179 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Wednesday, January 3. Vanover Kimberly E. had sold 772 shares worth $13,479. Another trade for 11,257 shares valued at $192,270 was sold by Mates Sharon. On Monday, October 2 ALAFI MOSHE bought $4.00 million worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) or 258,065 shares.

Clough Capital Partners L P, which manages about $5.01B and $1.49B US Long portfolio, decreased its stake in Tri Pointe Homes Inc (NYSE:TPH) by 28,000 shares to 497,271 shares, valued at $6.87 million in 2017Q3, according to the filing. It also reduced its holding in Nexpoint Cr Strategies Fd by 34,178 shares in the quarter, leaving it with 15,353 shares, and cut its stake in Ares Cap Corp (NASDAQ:ARCC).

Since August 25, 2017, it had 0 insider buys, and 1 sale for $65,700 activity.

Among 19 analysts covering CIT Group (NYSE:CIT), 8 have Buy rating, 0 Sell and 11 Hold. Therefore 42% are positive. CIT Group had 63 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, February 5 by Credit Suisse. Oppenheimer maintained the shares of CIT in report on Friday, August 11 with “Buy” rating. On Thursday, October 22 the stock rating was upgraded by Macquarie Research to “Outperform”. The stock has “Hold” rating by Wells Fargo on Friday, December 1. The stock of CIT Group Inc. (NYSE:CIT) has “Sell” rating given on Friday, October 6 by BMO Capital Markets. On Tuesday, October 17 the stock rating was initiated by Citigroup with “Buy”. Morgan Stanley maintained the shares of CIT in report on Monday, September 18 with “Equal-Weight” rating. The stock of CIT Group Inc. (NYSE:CIT) earned “Buy” rating by Oppenheimer on Tuesday, July 25. Stifel Nicolaus maintained it with “Buy” rating and $50 target in Monday, November 9 report. The stock has “Hold” rating by Keefe Bruyette & Woods on Monday, August 28.

Investors sentiment increased to 1.01 in 2017 Q3. Its up 0.67, from 0.34 in 2017Q2. It improved, as 23 investors sold CIT shares while 91 reduced holdings. 43 funds opened positions while 72 raised stakes. 134.52 million shares or 7.51% less from 145.43 million shares in 2017Q2 were reported. The Massachusetts-based Commonwealth Equity Ser has invested 0% in CIT Group Inc. (NYSE:CIT). Apg Asset Mngmt Nv reported 0.03% stake. Envestnet Asset Management holds 0.01% or 50,310 shares in its portfolio. Fny Managed Accounts Ltd invested in 564 shares. Us Natl Bank De invested 0% in CIT Group Inc. (NYSE:CIT). Pnc Financial Services Gru owns 0% invested in CIT Group Inc. (NYSE:CIT) for 13,330 shares. Twin Cap Mgmt holds 0.05% or 19,435 shares in its portfolio. Nordea Invest holds 0.02% or 136,148 shares. Janney Montgomery Scott Ltd Llc accumulated 0% or 5,256 shares. Quantbot Technologies Lp owns 41,947 shares for 0.2% of their portfolio. Spears Abacus Advsr Lc holds 592,992 shares. James Rech Inc holds 0.06% or 38,745 shares. Invesco Ltd holds 0% of its portfolio in CIT Group Inc. (NYSE:CIT) for 98,680 shares. Rhumbline Advisers holds 183,789 shares. Dupont Cap Mgmt holds 0.07% or 65,600 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: